LakeShore Biopharma (NASDAQ:LSB) provided guidance for the half year of its fiscal year of 2025 and reaffirmed its guidance for FY 2025. LakeShore said it estimates its preliminary total revenue for ...
Source LinkLakeShore Biopharma (NASDAQ:LSB) provided guidance for the half year of its fiscal year of 2025 and reaffirmed its guidance for FY 2025. LakeShore said it estimates its preliminary total revenue for ...
Source Link
Comments